Lonza, a global development and manufacturing partner to the pharmaceutical and biotech markets, has joined CMAC, a center for medicines manufacturing research, to enhance its service offering for particle technologies and drug product development and manufacture. 

CMAC is an international research hub with academic and industrial leaders in applied and pre-competitive research programs, based at the University of Strathclyde in Scotland. It aims to transform pharmaceutical manufacturing and crystallization processes by developing continuous manufacturing technologies, optimizing efficiency, and enhancing product quality.  

Lonza will gain access to CMAC’s network, which advances Chemistry, Manufacturing, and Control (CMC) technologies, implements digitalization strategies, and develops innovative continuous processing and crystallization solutions for active pharmaceutical ingredients and drug product technologies. 

Francois Ricard, Head of R&D, Advanced Synthesis, Lonza, said, “Our participation in CMAC will allow us to work with world-leading industry and academia experts and apply best practice in the fields of API development, continuous processing, drug product development, and overall digital CMC strategy. Our global team will drive the implementation of these processes and technologies across scales in a CDMO setup for the benefit of our customers and partners.”